NCT07517198 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07517198
Title	Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Indications	ovarian cancer prostate cancer neuroendocrine carcinoma stomach cancer lung non-small cell carcinoma renal cell carcinoma liver cancer head and neck squamous cell carcinoma triple-receptor negative breast cancer lung small cell carcinoma
Therapies	EXS74539
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
START Dallas	RECRUITING	Fort Worth	Texas	76104	United States	Details
START Mountain Region	RECRUITING	West Valley City	Utah	84119	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07517198Clinical Trial Detail